The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
News|Slideshows|May 8, 2024
Slideshow: Exercise May Fight Depression, Mindfulness Could Help Reduce Drug Use
Author(s)Killian Meara
With the mental health crisis worsening in the United States, recent research explores novel treatments and underlying causes.
Advertisement
The mental health crisis in the United States has steadily been worsening over the past several years and was further exacerbated by the COVID-19 pandemic. Three in 10 adults in the country now report experiencing anxiety and depression, suicide deaths reached an all-time high in 2022, and more than 111,000 people died from a drug overdose in the 12-month period ending April 2023.1,2,3 In order to deal with the public health emergency, which impacts all segments of society, expanded access to services, more mental health professionals, and new forms of treatment are desperately needed.
References
1. Panchal N, Saunders H, Rudowitz R, Cox C. The implications of COVID-19 for mental health and substance use. News Brief. KFF. March 20, 2023. Accessed January 22, 2024. https://www.kff.org/mentalhealth/issue-brief/the-implications-of-covid-19-for-mental-healthand-substance-use/
2. Curtin SC, Garnett MF, Ahmad FB. Provisional estimates of suicide by demographic characteristics: United States, 2022. CDC. November 29, 2023. Accessed January 22, 2024. https://stacks.cdc.gov/view/ cdc/135466
3. Rossen LM, Ahmad FB, Spencer MR, et al. Methods to adjust provisional counts of drug overdose deaths for underreporting. CDC. August 2018. Accessed January 22, 2024. https://www.cdc.gov/nchs/ data/nvss/vsrr/NVSS-methods-drug-adjustment.pdf
4. Rahmati M, Lee S, Yon DK, et al. Physical activity and prevention of mental health complications: An umbrella review. Neurosci Biobehav Rev. 2024;160:105641. doi:10.1016/j.neubiorev.2024.105641
5. Low intensity exercise linked to reduced depression. News Release. Anglia Ruskin University. April 24, 2024. Accessed May 8, 2024. https://www.eurekalert.org/news-releases/1042340
6. Cooperman NA, Lu S, Hanley AW, et al. Telehealth Mindfulness-Oriented Recovery Enhancement vs Usual Care in Individuals With Opioid Use Disorder and Pain: A Randomized Clinical Trial. JAMA Psychiatry. 2024;81(4):338–346. doi:10.1001/jamapsychiatry.2023.5138
7. Mindfulness training enhances opioid addiction treatment. News Release. Rutgers University. May 6, 2024. Accessed May 8, 2024. https://www.eurekalert.org/news-releases/1043655
8. Grummitt L, Baldwin JR, Lafoa’i J, et al. Burden of Mental Disorders and Suicide Attributable to Childhood Maltreatment. JAMA Psychiatry. Published online May 08, 2024. doi:10.1001/jamapsychiatry.2024.0804
9. Childhood maltreatment responsible for up to 40 percent of mental health conditions. News Release. University of Sydney. May 8, 2024. Accessed May 8, 2024. https://www.eurekalert.org/news-releases/1043738
Advertisement
Related to this article
The Milken Institute released survey results alongside new data regarding the need for pharmacists in extending effective GLP-1 care.
Through the ACCESS program, Mark Ey, RPh, notes that pharmacies can now start billing for a variety of services they’ve already been providing.
The medication significantly increased risk of pregnancy loss when compared with macrolide antibiotics, amoxicillin, and topical clindamycin for acne.
In part 3, Rebold explores improving the ART formulary protocol through introducing pharmacist-led transition-of-care services.
Our hosts explore why ketone monitoring matters, what pharmacists should know about Libre Duo, and how patient education can support proactive care management.
Mark Ey, RPh, details the patient-focused factors of the ACCESS to Pharmacy Care Program and the ways in which valued care translates to reimbursement.
A new option for adults who have experienced stroke will now be available to further reduce future risk.
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Adds NAION Eye Risk Warning to All GLP-1 Labels
2
The Pharmacy Model Creating New Billing Pathways, Improved Recognition
3
New Report Finds Pharmacies Key in Long-Term GLP-1 Success
4
Vaxcyte’s VAX-31 Pneumococcal Vaccine Meets All Phase 3 Primary Goals
5